Ixekizumab ist dem Placebo für die Behandlung von Nagel-, Kopfhaut- und palmoplantarer Psoriasis bei pädiatrischen Patienten mit mittelschwerer bis schwerer Plaque-Psoriasis überlegen
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Kernaussagen
- Ixekizumab, ein hochaffiner monoklonaler Antikörper, der selektiv gegen Interleukin-17A1 gerichtet ist, ist für die Behandlung der mittelschweren bis schweren Plaque-Psoriasis bei Erwachsenen zugelassen.
- Psoriasis kann bei Kindern Hautstellen betreffen, die bei Erwachsenen seltener vorkommen: Diese Studie untersuchte die Wirksamkeit und Sicherheit von Ixekizumab bei pädiatrischen Patienten (≥ 6 und < 18 Jahre) mit Nagel-, Kopfhaut- und palmoplantarer Psoriasis und bewertete die patientenberichteten Psoriasis-Schwere.
- Ixekizumab wirkte schnell und führte zu einer vollständigen Rückbildung von Kopfhaut-, Nagel- und palmoplantarer Psoriasis bei pädiatrischen Patienten.
Presenting Author
Amy S Paller, MD
Northwestern University, Chicago, IL, USA
Chair, Department of Dermatology
Director, Skin Biology and Diseases Resource-Based Center Walter J. Hamlin Professor of Dermatology
Professor of Dermatology and Pediatrics Dermatology
Dr. Paller studies the role of topically-applied, nanotherapy based gene therapy to treat skin disease, particularly diabetic ulcers, psoriasis, atopic dermatitis (eczema), skin cancer, and rare genetic skin problems. Her lab also focuses on unraveling the mechanism by which membrane-based glycosphingolipids modulate signaling, especially of the insulin-like growth factor-1 receptor (IGF-1R) and the epidermal growth factor receptor (EGFR) and studying the mechanism of the abnormal innervation in skin related to pain. Dr. Paller is the PI of Northwestern's Skin Disease Research Center, which includes 3 Cores dedicated to providing service to researchers of skin biology. As a pediatric dermatologist, Dr. Paller specializes in genetic (esp. ichthyoses and epidermolysis bullosa) and immune-mediated inflammatory (esp. atopic dermatitis, psoriasis and autoimmune disorders) in children. As director of pediatric dermatology clinical research, Dr. Paller has led almost 100 clinical trials. Her most recent translational research has: a) defined the immunophenotypes in early atopic dermatitis in children, paving the way for targeted therapy; b) discovered the immune dysregulation that may lead to inflamed skin in the ichthyoses, leading to a novel clinical trial with repurposed medication; and c) discovered evidence for an important role for ganglioside GM3 as an intermediate in the insulin resistance in diabetic skin and also in development of diabetic neuropathy.
Author disclosures
A. Paller has served as an investigator for: AbbVie, AnaptysBio, Eli Lilly and Company, Galderma, Incyte, Leo Pharma, Novartis, Regeneron, and Sanofi, and as a consultant for: AbbVie, Asana BioSciences, Dermavant, Dermira, Galderma, Eli Lilly and Company, Forté Pharma, Leo Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron, and Sanofi
